Weekly Roundup: September 13-17

POLL: How often do you treat hidradenitis suppurativa?

Dosing Starts in Tapinarof AD Trials

Dermavant has announced it has dosed the first patient in its phase 3 trial evaluating tapinarof cream for the treatment of moderate to severe atopic dermatitis.

FDA Warns About Some JAK Inhibitors

Although JAK inhibitors have shown efficacy in treating challenging conditions, federal regulators continue their safety reviews.

Study: 730 nm Picosecond Laser for Treatment of Lentigines

A recent study delved into how well the 730 nm picosecond-domain laser could treat facial and non-facial lentigines in patients.

Image-Guided Superficial Radiotherapy for BCC and SCC

New study data shows positive data for Image-Guided Superficial Radiotherapy (IGSRT) in treating basal cell carcinoma and squamous cell carcinoma.

Vitiligo Linked to Insomnia Risk

A new study showed about half of all vitiligo patients from a care system were burdened with the sleeping disorder.

Telehealth saw dip in June

The drop in use was starkest in the northeast.

Topical Remetinostat Effective, Tolerable in Basal Cell Carcinoma

The topical HDAC inhibitor remetinostat demonstrated favorable tolerability and clinically significant efficacy in reducing disease burden in patients with basal cell carcinoma, according to results from a phase 2 trial.

ACP speaks out against COVID-19 misinformation

The organization is also calling on everyone to be vaccinated against the disease.

Gut Microbiome Can Affect Radiation Cancer Treatment

The overgrowth of fungi could cause the immune system to stop fighting cancer, according to a study.

Derm-Biome Announces Positive Preclinical Data in AD trials

Derm-Biome’s topical compounds have positive results in preclinical trial.

Laser Therapy for Scars and Keloids

Jill Waibel, MD, discusses her recommendations on how to treat keloids and scaring using lasers in her presentation at the Skin of Color Update 2021.

New NRS Recommendations for Rosacea

The National Rosacea Society has recently released recommendations based on a group discussion regarding updates in rosacea.